- Home
- INSM
INSM
Insmed Incorporated
as 10-04-2024 4:00pm EST
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 12.5B | IPO Year: | 2000 |
| Target Price: | $82.00 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.92 - $80.53 | Next Earning Date: | 10-24-2024 |
| Revenue: | $328,605,000 | Revenue Growth: | 21.94% |
| Revenue Growth (this year): | 19.1% | Revenue Growth (next year): | 44.67% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Sep 10 '24 | Sell | $71.63 | 37,575 | $2,686,614.57 | 100,100 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Sep 6 '24 | Sell | $71.65 | 149,002 | $10,613,387.23 | 178,681 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Aug 12 '24 | Sell | $72.49 | 9,469 | $686,407.81 | 100,100 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Aug 12 '24 | Sell | $73.20 | 88,070 | $6,425,466.00 | 109,142 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insider Monkey
6 days ago
Is Insmed Incorporated (INSM) the Best Performing Long Term Stock in 2024?
Insider Monkey
9 days ago
Is Insmed Inc. (INSM) the Best Performing Stock in 2024?
Insider Monkey
14 days ago
Insmed Inc. (INSM): A Top Mid-Cap Biopharma Stock with Compelling Growth Potential
MT Newswires
19 days ago
Insmed Insider Sold Shares Worth $3,074,177, According to a Recent SEC Filing
MT Newswires
19 days ago
Insmed Insider Sold Shares Worth $2,072,223, According to a Recent SEC Filing
Insider Monkey
24 days ago
Insmed Incorporated (INSM) Surged Following Positive Data For its Drug
Insider Monkey
a month ago
Insmed Incorporated (INSM): Hedge Funds Are Recommending This Biotech Stock Now
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.